Haemonetics Corp. (HAE) Tops Q3 EPS by 6c; Affirms FY12 EPS Outlook
Get Alerts HAE Hot Sheet
Join SI Premium – FREE
Haemonetics Corp. (NYSE: HAE) reported Q3 EPS of $0.86, $0.06 better than the analyst estimate of $0.80. Revenue for the quarter came in at $191.2 million versus the consensus estimate of $186.21 million.
Affirms outlook.
For earnings history and earnings-related data on Haemonetics Corp. (HAE) click here.
Affirms outlook.
For earnings history and earnings-related data on Haemonetics Corp. (HAE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
- Vivos Therapeutics (VVOS) Tops Q2 EPS by 6c
- Paramount Global (PARA) Tops Q2 EPS by 175c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share